Contract R&D to Identify Drugs that Target Human Topo I, Topo II, Bacterial Topo IV and DNA Gyrase
These HR/NHEJ kits are cell based, meaning they have the HR or NHEJ GFP reporters pre-installed. A single plasmid (I-Sce1) is transfected to activate repair. Please see this table for a summary and comparison/application of each kit.
Homologous GFP Repair Systems
HeLa Cell HR Kit (I-Sce1 Based)
HeLa Cell HR Kit (CRISPR-CAS Based)
Human Neuroblastoma Cell Line SH-SY5Y using (I-Sce1 transfection)
Mouse 3T3 Cell Line using I-Sce1 transfection
Mouse Neuronal Cell Line using I-Sce1 transfection
Custom construction Kit to make your own HR Cell Reporter
NHEJ GFP Reporter
Systems
Transfection-based HR and NHEJ kits use transient transfections to make a pool of cells containing the DNA reporters to allow the investigator to interrogate the 2 major DNA repair pathways. The advantages are:
Contract Screening Services
TopoGEN has >20 yrs. experience in the area as a Contract Research Organization and we stand behind our results. We guarantee clear, cosmetic data and unambiguous interpretations. You will receive a publication quality product. We are seasoned veterans in the arena of in vitro testing. More importantly, we can help you develop a tractable strategy for analysis of drug mechanisms in the context of the tumor cell. We can evaluate potential genotoxicity independently from topo effects without extra charge. Finally, all our topo enzymes are homogeneously pure. We do not screen using extracts. Controls with specific drugs (e.g., etoposide vs. Topo IIa) guarantee specificity in all assays and validate even negative results with unknowns.
We save our clients considerable time and labor by offering services that are designed as a multi-tier approach to testing. For example, a limited scope screen (3-5 concentration inputs) is reasonable to quickly assess potential targeting. If the results are clearly negative, there is no need for follow-up. If we obtain a hit/lead, we will work closely with you to design next logical steps in a tier -2 testing strategy.
In all cases, we will craft a strategy with you to move ahead or not. Our screens are designed to reveal catalytic inhibition; however, because of the way the screens are set up, we can detect IFP action, if present (since some agents are dual mode). Because we cross reference our findings with topo drugs as positive and negative as controls, we obtain highly significant mechanistic details on drug action. For example as internal proof, we typically QC test topo II with both CPT and VP16 to show that IFP is specific to the former.
If you are interested you can complete our Quote Request Form and we will get back to you within 24 hours.